EVFM: AI 评分 51/100 — AI 分析 (4月 2026)

Evofem Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing products for women's sexual and reproductive health. Their lead product, Phexxi, is a non-hormonal vaginal gel for contraception.

Key Facts: Price: $0.01 AI Score: 51/100 Sector: Healthcare

公司概况

概要：

Evofem Biosciences offers a novel approach to women's reproductive health with Phexxi, a non-hormonal contraceptive vaginal gel, and a pipeline focused on preventing sexually transmitted infections, positioning them to capture a segment of the growing women's health market.

EVFM是做什么的？

Evofem Biosciences, Inc. is a biopharmaceutical company dedicated to addressing unmet needs in women's sexual and reproductive health. The company's journey began with a vision to provide women with innovative, hormone-free options for contraception and infection prevention. Their flagship product, Phexxi, is a vaginal gel approved for the prevention of pregnancy, offering a non-hormonal alternative to traditional birth control methods. This product represents a significant advancement in women's health, catering to a growing demand for hormone-free options. Beyond Phexxi, Evofem is developing EVO100, an antimicrobial vaginal gel designed to prevent urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections. This reflects the company's commitment to addressing a broader spectrum of women's health concerns. Headquartered in San Diego, California, Evofem operates with a focused team of 32 employees. While currently focused on the US market, future expansion could broaden their geographic reach. The company's competitive positioning is centered on its innovative, non-hormonal approach, differentiating it from established pharmaceutical companies offering traditional hormonal contraceptives.

EVFM的投资论点是什么？

Investing in Evofem Biosciences presents a compelling opportunity due to the increasing demand for non-hormonal contraceptive options. Phexxi's unique mechanism of action and its appeal to women seeking hormone-free alternatives position Evofem for growth within the $20 billion+ global contraceptive market. Key value drivers include increasing Phexxi adoption, successful clinical trials for EVO100, and potential partnerships for expanding market reach. The company's gross margin of 79.4% indicates strong pricing power. Upcoming catalysts include potential FDA approval and commercialization of EVO100, which could significantly expand Evofem's revenue streams. However, investors should be aware of the company's negative profit margin of -43.4% and the need for continued funding to support operations and research.

EVFM在哪个行业运营？

Evofem Biosciences operates within the women's health market, specifically targeting the contraception and infection prevention segments. The global contraceptive market is estimated to be over $20 billion, with a growing demand for non-hormonal options. Key competitors include established pharmaceutical companies offering traditional hormonal contraceptives, as well as companies developing alternative contraceptive methods. Evofem's focus on non-hormonal solutions and infection prevention differentiates it within this competitive landscape, positioning it to capture a segment of the market seeking innovative options.

Biotechnology

Healthcare

EVFM有哪些增长机遇？

Expanding Phexxi Market Share: Phexxi's unique non-hormonal formulation caters to a growing segment of women seeking alternatives to traditional hormonal contraceptives. Increased marketing efforts, strategic partnerships with healthcare providers, and direct-to-consumer advertising can drive adoption and expand market share within the $20 billion+ contraceptive market. Timeline: Ongoing.
EVO100 Development and Commercialization: Successful clinical trials and FDA approval of EVO100 for the prevention of Chlamydia and Gonorrhea infections would significantly expand Evofem's product portfolio and revenue streams. The market for STI prevention is substantial, with millions of cases reported annually. Timeline: 2027-2028.
Strategic Partnerships and Licensing Agreements: Collaborating with larger pharmaceutical companies or licensing Phexxi or EVO100 to expand market reach and distribution channels can accelerate growth. Partnerships can provide access to established sales forces and marketing infrastructure. Timeline: Ongoing.
Geographic Expansion: While currently focused on the US market, expanding into international markets with unmet needs for non-hormonal contraception and STI prevention can drive significant growth. Market entry strategies may include partnerships with local distributors or establishing a direct presence. Timeline: 2028-2030.
Development of New Products: Investing in research and development to expand the product pipeline with innovative solutions for women's health, such as treatments for menopause symptoms or other reproductive health conditions, can create long-term growth opportunities. Timeline: 2030+

Phexxi is the first and only FDA-approved non-hormonal vaginal gel for contraception.
Gross margin of 79.4% demonstrates strong pricing power for Phexxi.
EVO100 is in development for the prevention of urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections.
Market capitalization of $0.00B reflects the company's current financial challenges and growth potential.
Beta of -1.37 suggests the stock is less volatile than the market.

EVFM提供哪些产品和服务？

Develop and commercialize products for women's sexual and reproductive health.
Offer Phexxi, a non-hormonal vaginal gel for contraception.
Develop EVO100, an antimicrobial vaginal gel for STI prevention.
Address unmet needs in women's health with innovative solutions.
Provide hormone-free alternatives to traditional birth control methods.
Conduct clinical trials to evaluate the safety and efficacy of their products.
Seek regulatory approvals from the FDA for their products.

EVFM如何赚钱？

Develop and obtain regulatory approval for women's health products.
Manufacture and market Phexxi, their FDA-approved contraceptive gel.
Generate revenue through direct sales and partnerships.
Invest in research and development to expand their product pipeline.

Women seeking non-hormonal contraception options.
Healthcare providers who prescribe and recommend contraception methods.
Pharmacies and distributors that stock and sell women's health products.
Women seeking prevention of urogenital infections.

Proprietary non-hormonal formulation of Phexxi.
FDA approval for Phexxi, creating a barrier to entry.
Intellectual property protection for their products and technologies.
Focus on a niche market with unmet needs.

什么因素可能推动EVFM股价上涨？

Upcoming: Potential FDA approval and commercialization of EVO100 for STI prevention (2027-2028).
Ongoing: Increasing adoption and market share growth of Phexxi.
Ongoing: Strategic partnerships and licensing agreements to expand market reach.
Ongoing: Positive clinical trial results for EVO100 and other pipeline products.

EVFM的主要风险是什么？

Potential: Competition from established pharmaceutical companies and generic alternatives.
Potential: Regulatory delays or setbacks in drug development.
Ongoing: Dependence on Phexxi for revenue generation.
Ongoing: Need for continued funding to support operations and research.
Potential: Negative publicity or safety concerns regarding Phexxi or EVO100.

EVFM的核心优势是什么？

Unique non-hormonal contraceptive option (Phexxi).
Potential for EVO100 to address a significant unmet need in STI prevention.
High gross margin on Phexxi sales.
Dedicated focus on women's sexual and reproductive health.

EVFM的劣势是什么？

Limited product portfolio with reliance on Phexxi.
Negative profit margin and ongoing need for funding.
Relatively small company size and limited resources.
Challenging market penetration in a competitive contraceptive market.

EVFM有哪些机遇？

Expanding market share for Phexxi through targeted marketing.
Successful development and commercialization of EVO100.
Strategic partnerships to expand market reach and distribution.
Geographic expansion into international markets.

EVFM面临哪些威胁？

Competition from established pharmaceutical companies with hormonal contraceptives.
Potential for generic competition if Phexxi's patent protection expires.
Regulatory hurdles and delays in drug development.
Changes in healthcare policies and reimbursement rates.

EVFM的竞争对手是谁？

Bicara Therapeutics Inc — Focuses on bifunctional antibodies for cancer therapy. — (BICTF)
Biopharma Inc — Unknown business description. — (BINP)
Biora Therapeutics Inc — Develops targeted therapeutics for inflammatory diseases. — (BIOR)
BioMatrix Specialty Pharmacy — Specialty pharmacy services. — (BMMJ)
Bio-Path Holdings Inc — Develops RNAi nanoparticle drugs for cancer. — (BPTH)

Key Metrics

Price: $0.01 (+0.00%)
Market Cap: $1.1M
MoonshotScore: 51/100

Company Profile

CEO: Saundra Pelletier
Headquarters: San Diego, CA, US
Employees: 32
Founded: 2014

AI Insight

Stock data pending update.

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Evofem Biosciences, Inc. do?

Evofem Biosciences is a biopharmaceutical company focused on developing and commercializing innovative products for women's sexual and reproductive health. Their primary product is Phexxi, a non-hormonal vaginal gel used for contraception. They are also developing EVO100, an antimicrobial vaginal gel intended to prevent urogenital transmission of Chlamydia and Gonorrhea. The company aims to provide women with hormone-free alternatives and address unmet needs in reproductive health, differentiating themselves from traditional pharmaceutical companies.

Is EVFM stock a good buy?

Evaluating EVFM requires careful consideration of its potential and risks. The company's innovative product, Phexxi, addresses a growing demand for non-hormonal contraception, and EVO100 could further expand their market reach. However, the company's negative profit margin (-43.4%) and reliance on Phexxi sales are significant risks. Investors should weigh the potential for growth against the financial challenges and competitive landscape before making an investment decision. Monitor upcoming catalysts like EVO100's development progress.

What are the main risks for EVFM?

Evofem Biosciences faces several key risks. Competition from established pharmaceutical companies with well-established hormonal contraceptives poses a significant threat. The company's reliance on Phexxi for revenue makes them vulnerable to market fluctuations and potential generic competition. Securing continued funding to support operations and research is crucial, and any difficulties in raising capital could hinder growth. Regulatory hurdles and potential delays in the development of EVO100 also present risks.